Micronutrient risk with GLP-1 receptor and dual incretin agonists in obesity: Mechanistic pathways, clinical signals, and a monitoring framework.

Summary

BACKGROUND: Incretin-based pharmacotherapies, including GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists, have transformed obesity management by producing substantial weight loss through appetite suppression, reduced energy intake, and gastrointestinal effects.

Clinical Relevance

This publication has potential implications for gastroenterology and endoscopy nursing practice. GI nursing professionals should review the full source material to assess how these findings may affect unit protocols, patient care workflows, or professional development.

Bottom Line

Stay current with developments like this to maintain evidence-based practice standards in your GI/endoscopy unit.